BioSpace News Archive

TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology, announced topline results from the TLC590 Phase II clinical trial, a randomized, double-blind, placebo- and comparator- controlled study of TLC590 in patients following bunionectomy.

Innovent Biologics, Inc. announced the Phase 1b preliminary clinical study data of TYVYT® in combination with IBI305, a bevacizumab biosimilar independently developed by Innovent, in the treatment of advanced hepatocellular carcinoma at the 56th Annual Meeting of the American Society of Clinical Oncology.

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines, jointly announced with Eli Lilly and Company the results of TYVYT® ORIENT-2 study, a pivotal clinical study of second-line treatment for locally advanced or metastatic esophageal squamous cell carcinoma at the 56th Annual Meeting of the American Society of Clinical Oncology .

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines, jointly announced with Eli Lilly and Company the research results of TYVYT® ORIENT-1 study for the treatment of relapsed or refractory classic Hodgkin’s lymphoma, at the 56th Annual Meeting of the American Society of Clinical Oncology .

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, announced the launch of two new oncology tests designed to equip physicians with even more precise genomic data in an effort to improve therapeutic outcomes.

Taiho Oncology, Inc. announced efficacy and safety results of an interim analysis of FOENIX-CCA2, a single-arm multicenter Phase 2 study evaluating futibatinib in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements, who have failed at least one line of therapy.

Tobacco is the leading preventable cause of premature death and disease in Canada.

First data from this collaboration study with Merck KGaA, Darmstadt, Germany, and Pfizer Inc and sponsor, IKF, presented at ASCO

Hua Medicine, a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, is pleased to announce that the Company has been officially included as a constituent stock of the MSCI Hong Kong Micro Cap Index.

Pre-clinical data for Celltrion’s antiviral antibody treatment candidate demonstrate a 100-fold reduction in viral load of SARS-CoV-2 (COVID-19), as well as improvement in lung lesions